The S&P/ASX 50 index is home to 50 of the largest listed companies on the Australian share market. This means the index hosts many of the highest quality and most well-known companies that the ANZ region has to offer.
While not all the shares on the index are necessarily in the buy zone, two that could be are listed below. Here's what you need to know about them:
Image source: Getty Images
Goodman Group (ASX: GMG)
Goodman Group could be an ASX 50 share to look closely at. It is one of the world's leading integrated commercial and industrial property companies.
Goodman owns, develops, and manages industrial real estate globally. This includes warehouses, large scale logistics facilities, and business and office parks. At the last count, Goodman had $52.9 billion of total assets under management globally, 366 properties under management, and 1,600+ customers.
It has been growing at a solid rate over the last decade thanks to the overwhelming success of its strategy. Goodman focuses on investing in and developing high quality industrial properties in strategic locations, close to large urban populations and in and around major gateway cities globally.
This is where demand is strong and transformational changes are driving significant opportunities. Key locations include gateway cities such as LA, Paris, Sydney, Shanghai, and Tokyo.
One leading broker that appears confident its positive form will continue is Morgan Stanley. The broker currently has an overweight rating and $23.00 price target on its shares.
Ramsay Health Care Limited (ASX: RHC)
Another ASX 50 share to look at is Ramsay Health Care. It provides quality healthcare services through a global network of facilities that extend across 10 countries. Each year there are over eight million admissions/patient visits across its 500 locations.
But it isn't stopping there. Ramsay is currently in the process of trying to bolster its network in the United Kingdom market with the proposed acquisition of Spire Healthcare for ~$1.9 billion. This is expected to create a leading private health care services provider in the UK.
Outside this, the company looks well-positioned for growth in the short term from a post-pandemic backlog in surgeries and in the long term from the global ageing populations tailwind.
Citi is positive on the company. The broker recently upgraded the company's shares to a buy rating from neutral and increased its price target to $76.00.
